Two Better Than One: Combination bNAbs Hold Potential for HIV Advance

People with HIV who receive a single broadly neutralizing antibody (bNAb) have a slight delay in HIV rebound when antiretroviral therapy (ART) is stopped but rapidly develop resistance to the bNAb. Now, investigators have evaluated whether infusing two bNAbs is able to maintain HIV suppression for a longer time.

A total of 11 participants on ART with undetectable HIV RNA levels received three infusions, spaced 3 weeks apart, of both 3BNC117, which binds to the CD4 binding site on the HIV envelope, and 10-1074, which binds the envelope V3 loop and glycans. ART was stopped 2 days after the first infusion.

The median time to HIV rebound was 21 weeks, as compared with 2.3 weeks for historical controls who did not receive an intervention and 6 to …